Related references
Note: Only part of the references are listed.Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development
Paolo Tarantino et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A. Conley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot et al.
NATURE MEDICINE (2021)
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Erez N. Baruch et al.
SCIENCE (2021)
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
Abirami Sivapiragasam et al.
CANCER MEDICINE (2021)
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality
Paolo Tarantino et al.
CANCER TREATMENT REVIEWS (2021)
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials
Paolo Tarantino et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Immunotherapy as a partner for HER2-directed therapies
Guy T. Clifton et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
The Global Landscape of Treatment Standards for Breast Cancer
Dario Trapani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
Tess A. O’Meara et al.
Oncotarget (2021)
Human Microbiota and Breast Cancer-Is There Any Relevant Link?-A Literature Review and New Horizons Toward Personalised Medicine
Diogo Alpuim Costa et al.
FRONTIERS IN MICROBIOLOGY (2021)
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano et al.
CLINICAL CANCER RESEARCH (2021)
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2021)
Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
Jose M. Perez-Garcia et al.
EUROPEAN JOURNAL OF CANCER (2021)
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S. Alva et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer
Alice Tzeng et al.
GENOME MEDICINE (2021)
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan Goldberg et al.
FRONTIERS IN IMMUNOLOGY (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab plus pertuzumab plus trastuzumab plus chemotherapy (neoadj A plus PH plus CT) in high-risk, HER2-positive early breast cancer (EBC)
J. Huober et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
P. Schmid et al.
ANNALS OF ONCOLOGY (2021)
The tumor microenvironment (TME) and atezolizumab plus nab-paclitaxel (A plus nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)-Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer
Hope S. Rugo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Thomas Powles et al.
NATURE (2021)
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
N. Colombo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
D. F. Bajorin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
Guangchun Han et al.
NATURE COMMUNICATIONS (2021)
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
Shu-Jin Li et al.
CANCER COMMUNICATIONS (2021)
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
Romualdo Barroso-Sousa et al.
NPJ BREAST CANCER (2021)
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies
Xinran Wang et al.
NPJ BREAST CANCER (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
R. Barroso-Sousa et al.
ANNALS OF ONCOLOGY (2020)
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Romualdo Barroso-Sousa et al.
CLINICAL CANCER RESEARCH (2020)
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab for the treatment of colorectal cancer
Dahna Coupez et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Ami N. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
Delvys Rodriguez-Abreu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
Eric P. Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immunotherapy for pancreatic cancer: A 2020 update
Dimitrios Schizas et al.
CANCER TREATMENT REVIEWS (2020)
Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
D. W. Miles et al.
ANNALS OF ONCOLOGY (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: fi nal results from a phase I/II, single-arm, basket trial
K. Kalinsky et al.
ANNALS OF ONCOLOGY (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens et al.
LANCET ONCOLOGY (2020)
How current assay approval policies are leading to unintended imprecision medicine
Roberto Salgado et al.
LANCET ONCOLOGY (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M. Tolaney et al.
JAMA ONCOLOGY (2020)
Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
Carin A. Uyl-de Groot et al.
CANCERS (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein et al.
NATURE CANCER (2020)
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
S. Trebeschi et al.
ANNALS OF ONCOLOGY (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Defining the immunogram of breast cancer: a focus on clinical trials
Paolo Tarantino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy
Adrienne G. Waks et al.
CLINICAL CANCER RESEARCH (2019)
Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.
Romualdo Barroso-Sousa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
A. Elkrief et al.
ANNALS OF ONCOLOGY (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
E. Krasniqi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086
Sherene Loi et al.
CANCER RESEARCH (2019)
Gut Microbiome and Breast Cancer in the Era of Cancer Immunotherapy
Romualdo Barroso-Sousa et al.
CURRENT BREAST CANCER REPORTS (2019)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Immunotherapy of Primary Brain Tumors: Facts and Hopes
Robin A. Buerki et al.
CLINICAL CANCER RESEARCH (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011+/- nivolumab (nivo) in patients (pts) with advanced cancers.
Timothy Anthony Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
57PDTumor mutational burden and prognosis across pan-cancers
H Ding et al.
ANNALS OF ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Clinical validity and Utility of Tumor-infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
Lironne Wein et al.
FRONTIERS IN ONCOLOGY (2017)
The genomic landscape of breast cancer and its interaction with host immunity
Stephen Luen et al.
BREAST (2016)
Prognostic and predictive value of tumor in early breast cancer
Carmen Criscitiello et al.
CANCER TREATMENT REVIEWS (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
Rajarsi Mandal et al.
CANCER DISCOVERY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The immunogenicity of breast cancer-molecular subtypes matter
C. Denkert
ANNALS OF ONCOLOGY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)